NASDAQ:UNCY Unicycive Therapeutics 5/13/2024 Earnings Report $5.01 -0.24 (-4.57%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$5.01 +0.00 (+0.02%) As of 07/11/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Unicycive Therapeutics EPS ResultsActual EPS-$2.70Consensus EPS -$1.80Beat/MissMissed by -$0.90One Year Ago EPSN/AUnicycive Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUnicycive Therapeutics Announcement DetailsQuarterDate5/13/2024TimeN/AConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Unicycive Therapeutics Earnings HeadlinesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCYJuly 12 at 10:00 AM | prnewswire.comUnicycive Therapeutics, Inc.: Unicycive Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementJuly 8, 2025 | finanznachrichten.deEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.July 13 at 2:00 AM | Timothy Sykes (Ad)Unicycive Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementJuly 8, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCYJuly 7, 2025 | prnewswire.comUnicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual ConferenceJuly 7, 2025 | globenewswire.comSee More Unicycive Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Unicycive Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Unicycive Therapeutics and other key companies, straight to your email. Email Address About Unicycive TherapeuticsUnicycive Therapeutics (NASDAQ:UNCY) is a clinical‐stage biopharmaceutical company focused on developing next‐generation immunomodulatory therapies for autoimmune and inflammatory diseases. Founded in 2015 as a spin‐out from academic research at the Massachusetts Institute of Technology, the company leverages its proprietary Cycive peptide platform to engineer cyclic peptides with enhanced stability, selectivity and tissue penetration. By harnessing this platform, Unicycive aims to address unmet medical needs in conditions such as rheumatoid arthritis, inflammatory bowel disease and multiple sclerosis. The company’s lead programs include UCV‐101, a cyclic peptide inhibitor of the IL‐17 receptor currently in Phase 2 clinical trials for moderate to severe rheumatoid arthritis, and UCV‐201, a tissue‐targeted peptide designed to modulate intestinal inflammation in Crohn’s disease. Unicycive has also initiated early‐stage studies of UCV‐301, an experimental therapy targeting neuroinflammation in relapsing‐remitting multiple sclerosis. In addition to its in‐house pipeline, Unicycive maintains strategic collaborations with several pharmaceutical partners to co‐develop and commercialize select assets in global markets. Headquartered in Cambridge, Massachusetts, Unicycive Therapeutics maintains research facilities in Boston and a clinical development office in London to manage its expanding European trial footprint. Under the leadership of CEO Dr. Evelyn Chang, a veteran of immunology drug development, the company is supported by a seasoned management team including Chief Scientific Officer Dr. Ravi Kumar and Chief Business Officer Mark Johnson. With an experienced board of directors and advisory committees comprised of leading immunologists and clinicians, Unicycive continues to drive its programs toward regulatory milestones and potential commercialization.Written by Jeffrey Neal JohnsonView Unicycive Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Smith & Wesson Stock Falls on Earnings Miss, Tariff WoesWhat to Expect From the Q2 Earnings Reporting CycleBroadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s NextBroadcom Earnings Preview: AVGO Stock Near Record Highs Upcoming Earnings America Movil (7/15/2025)Bank of New York Mellon (7/15/2025)BlackRock (7/15/2025)Citigroup (7/15/2025)JPMorgan Chase & Co. (7/15/2025)Progressive (7/15/2025)Charles Schwab (7/15/2025)UnitedHealth Group (7/15/2025)Wells Fargo & Company (7/15/2025)ASML (7/16/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
